11 citations
,
April 2020 in “Andrology” Testosterone replacement therapy, especially intramuscular, raises PSA levels, but no overall link between PSA and testosterone was found except in non-BPH patients.
237 citations
,
December 2001 in “Urology” Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.
75 citations
,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
39 citations
,
February 2011 in “The Prostate/The prostate” Some men's prostate tissues have low enzyme levels due to genetic changes, possibly affecting treatment for prostate enlargement.
21 citations
,
February 2021 in “Frontiers in Endocrinology” Hormones affect prostate health and disease, with certain hormone imbalances linked to prostate cancer and benign prostatic hyperplasia.
21 citations
,
August 1994 in “Clinical endocrinology” 5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.
13 citations
,
May 2018 in “Urologic Oncology: Seminars and Original Investigations” Finasteride does not prevent bladder cancer.
12 citations
,
November 2024 in “Plants” Phytosterols may help manage prostate issues but are less effective than synthetic drugs.
6 citations
,
January 2016 in “International Journal of Trichology” The conclusion is that more hair loss (androgenetic alopecia) is linked to larger prostate size, suggesting hair loss could be an early sign of benign prostatic hyperplasia.
3 citations
,
March 2016 in “Phytotherapy Research” The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
3 citations
,
October 2011 in “QJM” The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.
2 citations
,
December 2006 in “Lancet Oncology” Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.
March 2026 in “Journal of Multidisciplinary Applied Natural Science” Cosmos caudatus extract is as effective as finasteride for treating benign prostatic hyperplasia without its side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
December 2024 in “Journal of Cancer Therapy and Research” Artocarpus heterophyllus seed extract may help treat prostate inflammation without side effects.
October 2017 in “The Journal of Urology” Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.
March 2016 in “National Repository of Dissertations in Serbia” Dutasteride is more cost-effective than finasteride for treating benign prostatic hyperplasia in Montenegro.
December 2010 in “Actas Urológicas Españolas” Taking dutasteride for one month before prostate surgery can reduce bleeding.
March 2009 in “The Journal of Urology” Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.
June 2007 in “Nature Clinical Practice Urology” Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.
January 2005 in “Metas de Enfermería” Serenoa repens may help with prostate issues, but more research is needed to confirm its effectiveness.
53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
4 citations
,
March 2017 in “Al-Mi’galaẗ al-sa'udiyaẗ lī-ulum al-ḥayaẗ” Leonuri Herba alkaloids may help treat hormone-induced enlarged prostate in rats.
January 2012 in “Курский научно-практический вестник "Человек и его здоровье"” 5-alpha-reductase inhibitors can effectively treat benign prostatic hyperplasia.
218 citations
,
December 2011 in “Advances in Urology” The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.
124 citations
,
September 1992 in “Endocrinology” The human type II 5α-reductase gene, linked to certain male health conditions, has a specific structure and low similarity to other related genes.
56 citations
,
November 2007 in “Molecular and cellular endocrinology” Two enzymes regulate androgen receptor activity, affecting treatments for androgen insufficiency and benign prostatic hyperplasia.
54 citations
,
November 2001 in “Urology” The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.
49 citations
,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.